Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma

• Status: Completed
• Trial end date: 2019-04-08
• Target enrollment: 0
• Participant gender: All

Summary

Although there seems to be no benefit from improving the histologic response rate or long-term survival of intra-arterial infusion of cisplatin for localized osteosarcoma of extremities with IOR/OS-3, IOR/OS-5, and COSS 86 protocols, such a treatment strategy is still believed to potentially increase the tumoricidal effect with an increase in higher local concentrations of the infused agents combined with longer tissue exposure time. Besides, the relationship of chemotherapy-induced necrosis and surgical margins is still the main concern for localized osteosarcoma patients to achieve long-term survival. The investigators intend to analyze the gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma in the past six years.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• histological diagnosis of high-grade osteosarcoma

• located at extremities

• following the PKUPH-OS protocol

• accept to recieve IA or IV infusion of cisplatin

Exclusion Criteria:

• lost to follow-up

• did not recieve definitve surgery in Musculoskeletal Tumor Center of Peking University People's Hospital

• quiting to recieve chemotherapy